SynapCell signs epilepsy research agreement with MedGenesis
MedGenesis said GDNF has already showed disease-modifying potential in treating parkinson’s disease and now will be evaluated for epilepsy. SynapCell will provide a detailed review of the effects
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.